Zevaskyn (prademagene zamikeracel) for wound treatment in individuals with recessive dystrophic epidermolysis bullosa: A therapeutics bulletin of the American College of Medical Genetics and Genomics (ACMG)
Genetics in Medicine Open · 2026-08 · 104408
DOI: 10.1016/j.gimo.2026.104408 ↗Kurz gefasst
Fachartikel in der Zeitschrift Genetics in Medicine Open, 2026-08. Verfasst von Amanda Thomas-Wilson und 3 weiteren Autor:innen. Die Arbeit nennt 14 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Kein Abstract verfügbar.
Zitieren
APA
Thomas-Wilson, A., Svoboda, M., Taliercio, V., & Abul-Husn, N. S. (2026). Zevaskyn (prademagene zamikeracel) for wound treatment in individuals with recessive dystrophic epidermolysis bullosa: A therapeutics bulletin of the American College of Medical Genetics and Genomics (ACMG). Genetics in Medicine Open, 104408. https://doi.org/10.1016/j.gimo.2026.104408
Vancouver
Thomas-Wilson A, Svoboda M, Taliercio V, Abul-Husn NS. Zevaskyn (prademagene zamikeracel) for wound treatment in individuals with recessive dystrophic epidermolysis bullosa: A therapeutics bulletin of the American College of Medical Genetics and Genomics (ACMG). Genetics in Medicine Open. 2026:104408. doi:10.1016/j.gimo.2026.104408
BibTeX
@article{ThomasWilson2026,
author = {Thomas-Wilson, Amanda and Svoboda, Marek and Taliercio, Vanina and Abul-Husn, Noura S.},
title = {Zevaskyn (prademagene zamikeracel) for wound treatment in individuals with recessive dystrophic epidermolysis bullosa: A therapeutics bulletin of the American College of Medical Genetics and Genomics (ACMG)},
journal = {Genetics in Medicine Open},
year = {2026},
pages = {104408},
doi = {10.1016/j.gimo.2026.104408}
}
EUVIMED